Critical limb ischemia

Current Treatment Options in Cardiovascular Medicine

Volumn 12, Issue 3, 2010, Pages 214-229

  Schanzer, Andres ^b   Conte, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACLITAXEL; PROSTAGLANDIN; SCATTER FACTOR;

AORTOFEMORAL BYPASS; ARTERIOVENOUS FISTULA; ARTERY BYPASS; ARTERY DISEASE; ARTERY OCCLUSION; ARTIFICIAL EMBOLISM; ATHERECTOMY; BLEEDING; BYPASS SURGERY; CELL THERAPY; CIGARETTE SMOKING; CLAUDICATION; CONTRAST INDUCED NEPHROPATHY; COST EFFECTIVENESS ANALYSIS; CRITICAL LIMB ISCHEMIA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG ELUTING STENT; ENDARTERECTOMY; ENDOVASCULAR SURGERY; FALSE ANEURYSM; GANGRENE; GENE THERAPY; GENE TRANSFER; HEART PROTECTION; HUMAN; HYPERTRIGLYCERIDEMIA; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; KIDNEY FAILURE; LEG REVASCULARIZATION; LIFESTYLE MODIFICATION; LIMB AMPUTATION; LIMB ISCHEMIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; SMOKING CESSATION; SPINAL CORD STIMULATION; STENT; SURGICAL RISK; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; ULCER; VASCULAR PATENCY;

EID: 77953534599     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-010-0076-7     Document Type: Review

References (74)

1. Criqui MH, Langer RD, Fronek A, et al.: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992, 326:381-386.
2. Hirsch AT, Hartman L, Town RJ, Virnig BA: National health care costs of peripheral arterial disease in the Medicare population. Vasc Med 2008, 13:209-215.
3. McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991, 87:119-128.
4. Murabito JM, Evans JC, Nieto K, et al.: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002, 143:961-965.
5. Howell MA, Colgan MP, Seeger RW, et al.: Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989, 9:691-696; discussion 696-697.
6. Adam DJ, Beard JD, Cleveland T, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366:1925-1934.
7. Stoyioglou A, Jaff MR: Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol 2004, 15:1197-1207.
8. Steg PG, Bhatt DL, Wilson PW, et al.: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297:1197-1206.
9. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005, 5:14.
10. Norgren L, Hiatt WR, Dormandy JA, et al.: TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5-S67. These are the current guidelines for treatment from the Transatlantic Inter-Society Working Group. (Pubitemid 46151680)
11. DeRubertis BG, Faries PL, McKinsey JF, et al.: Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg 2007, 246:415-422; discussion 422-424.
12. Goodney PP, Beck AW, Nagle J, et al.: National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 2009, 50:54-60.
13. Hirsch AT, Haskal ZJ, Hertzer NR, et al.: American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation: ACC/ AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter- Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-e654.
14. Price JF, Mowbray PI, Lee AJ, et al.: Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999, 20:344-353.
15. Brass EP, Anthony R, Dormandy J, et al.: Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006, 43:752-759.
16. Heart Protection Study Collaborative Group: MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
17. Feringa HH, Karagiannis SE, van Waning VH, et al.: The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007, 45:936-943.
18. Schillinger M, Exner M, Mlekusch W, et al.: Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004, 25:742-748.
19. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308:81-106.
20. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
21. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996, 335:1713-1720.
22. Schanzer A, Hevelone N, Owens CD, et al.: Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008, 47:774-781.
23. Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making. J Vasc Surg 2010 (In press).
24. Forbes J, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischemia of the leg (BASIL) trial: health-related quality of life, resource utilization and cost-effectiveness analysis. J Vasc Surg 2010 (In press).
25. Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010 (In press). This article discusses long-term follow-up in the BASIL trial by treatment received.
26. Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a description of the severity and extent of disease using the Bollinger angiogram scoring method and the TASC II classification. J Vasc Surg 2010 (In press).
27. Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention to treat analysis of amputation free and overall survival in patients randomised to a bypass surgery first or a balloon angioplasty first strategy. J Vasc Surg 2010 (In press). This article discusses long-term follow-up in the BASIL trial by treatment assigned.
28. Conte MS: BASIL and the (hoped for) dawn of evidence- based treatment for advanced limb ischemia. J Vasc Surg 2010 (In press).
29. Kasapis C, Henke PK, Chetcuti SJ, et al.: Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 2009, 30:44-55.
30. Stoner MC, Defreitas DJ, Manwaring MM, et al.: Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. J Vasc Surg 2008, 48:1489-1496.
31. Conte MS, Bandyk DF, Clowes AW, et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006, 43:742-751; discussion 751.
32. Cronenwett JL, Likosky DS, Russell MT, et al.: A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). J Vasc Surg 2007, 46:1093- 1101; discussion 101-102.
33. Conte MS, Bandyk DF, Clowes AW, et al.: Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005, 42:456- 464; discussion 464-465.
34. Goodney PP, Likosky DS, Cronenwett JL: Predicting ambulation status one year after lower extremity bypass. J Vasc Surg 2009, 49:1431-1439 e1.
35. Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with amputation or graft occlusion 1 year after lower extremity bypass in northern New England. Ann Vasc Surg 2010, 24:57-68.
36. Schanzer A, Goodney PP, Li Y, et al.: Validation of the PIII CLI risk score for the prediction of amputation- free survival in patients undergoing infrainguinal autogenous vein bypass for critical limb ischemia. J Vasc Surg 2009, 50:769-775; discussion 775.
37. Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with death 1 year after lower extremity bypass in northern New England. J Vasc Surg 2010, 51:71-78.
38. Nguyen LL, Brahmanandam S, Bandyk DF, et al.: Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg 2007, 46:1191-1197.
39. Schanzer A, Hevelone N, Owens CD, et al.: Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg 2007, 46:1180-1190; discussion 1190.
40. Conte MS, Geraghty PJ, Bradbury AW, et al.: Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009, 50:1462- 73.e3. This article provides suggested performance goals for devices targeting CLI, generated by a working group from the Society for Vascular Surgery.
41. Nguyen LL, Moneta GL, Conte MS, et al.: Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg 2006, 44:977- 983; discussion 983-984.
42. Nguyen LL, Hevelone N, Rogers SO, et al.: Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. Circulation 2009, 119:123-130.
43. Berceli SA, Hevelone ND, Lipsitz SR, et al.: Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis ofmidtermoutcomes fromthe PREVENT III trial. J Vasc Surg 2007, 46:1173-1179.
44. Albers M, Romiti M, Brochado-Neto FC, et al.: Metaanalysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006, 43:498-503.
45. Schanzer A, Mega J, Meadows J, et al.: Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. J Vasc Surg 2008, 48:1464-1471.
46. Conte MS, Lorenz TJ, Bandyk DF, et al.: Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg 2005, 39:15-23.
47. Ubbink DT, Vermeulen H: Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2003, CD004001.
48. Labropoulos N, Leon Jr LR, Bhatti A, et al.: Hemodynamic effects of intermittent pneumatic compression in patients with critical limb ischemia. J Vasc Surg 2005, 42:710-716.
49. Kavros SJ, Delis KT, Turner NS, et al.: Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. J Vasc Surg 2008, 47:543-549.
50. Sneider EB, Nowicki PT, Messina LM: Regenerative medicine in the treatment of peripheral arterial disease. J Cell Biochem 2009, 108:753-761.
51. Powell RJ, Simons M, Mendelsohn FO, et al.: Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58-65.
52. Nikol S, Baumgartner I, Van Belle E, et al.: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008, 16:972-978.
53. Rajagopalan S, Mohler 3rd ER, Lederman RJ, et al.: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
54. Makinen K, Manninen H, Hedman M, et al.: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Mol Ther 2002, 6:127-133.
55. Kusumanto YH, van Weel V, Mulder NH, et al.: Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006, 17:683-691.
56. Tateishi-Yuyama E, Matsubara H, Murohara T, et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bonemarrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
57. Lenk K, Adams V, Lurz P, et al.: Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005, 26:1903-1909.
58. Tepe G, Schmitmeier S, Speck U, et al.: Advances on drug-coated balloons. J Cardiovasc Surg (Torino) 2010, 51:125-143.
59. Scheller B, Speck U: Potential solutions to the current problem: coated balloon. EuroIntervention 2008, 4:C63-C66.
60. Tepe G, Zeller T, Albrecht T, et al.: Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008, 358:689-699.
61. Bosiers M, Peeters P, D'Archambeau O, et al.: AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol 2009, 32:424-435.
62. Laird JR, Zeller T, Gray BH, et al.: Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther 2006, 13:1-11.
63. Bosiers M, Deloose K, Verbist J, Peeters P: Nitinol stenting for treatment of 'below-the-knee' critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation. J Cardiovasc Surg 2007, 48:455-461.
64. DeRubertis BG, Pierce M, Ryer EJ, et al.: Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg 2008, 47:101-108.
65. Giles KA, Pomposelli FB, Spence TL, et al.: Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008, 48:128-136.
66. Romiti M, Albers M, Brochado-Neto FC, et al.: Metaanalysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008, 47:975-981.
67. Robinson 3rd WP, Owens CD, Nguyen LL, et al.: Inferior outcomes of autogenous infrainguinal bypass in Hispanics: an analysis of ethnicity, graft function, and limb salvage. J Vasc Surg 2009, 49:1416-1425.
68. Owens CD, Ho KJ, Kim S, et al.: Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg 2007, 45:944-952.
69. Biancari F, Salenius JP, Heikkinen M, et al.: Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a Finnvasc registry study. World J Surg 2007, 31:217-225; discussion 226-227.
70. Rossi PJ, Skelly CL, Meyerson SL, et al.: Redo infrainguinal bypass: factors predicting patency and limb salvage. Ann Vasc Surg 2003, 17:492-502.
71. Toursarkissian B, D'Ayala M, Stefanidis D, et al.: Angiographic scoring of vascular occlusive disease in the diabetic foot: relevance to bypass graft patency and limb salvage. J Vasc Surg 2002, 35:494-500.
72. Alback A, Biancari F, Saarinen O, Lepantalo M: Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score. Eur J Vasc Endovasc Surg 1998, 15:220-224.
73. Simons J, Goodney PG, Nolan B, et al.: Failure to achieve clinical improvement despite graft patency in patients undergoing lower extremity bypass for critical limb ischemia. J Vasc Surg 2010 (In press).
74. Taylor SM, Kalbaugh CA, Blackhurst DW, et al.: Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions. J Vasc Surg 2006, 44:747-755; discussion 755-756.